Profile data is unavailable for this security.
About the company
Beijing Hotgen Biotech Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. The Company's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The Company primarily conducts its businesses in domestic and overseas markets.
- Revenue in CNY (TTM)520.50m
- Net income in CNY-67.64m
- Incorporated2005
- Employees1.04k
- LocationBeijing Hotgen Biotech Co LtdYard 26 Yongwang West Rd, Daxing DistBEIJING 102629ChinaCHN
- Phone+86 1 050973660
- Fax+86 1 056528861
- Websitehttp://www.hotgen.com.cn/
More ▼
Mergers & acquisitions
| Acquired company | 688068:SHH since announced | Transaction value |
|---|---|---|
| Beijing Keygen Technology Co Ltd | 11.89% | 1.52m |
Data delayed at least 15 minutes, as of Nov 15 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Cowin Biotech Co Ltd | 118.17m | -144.51m | 2.59bn | 657.00 | -- | 1.69 | -- | 21.93 | -1.30 | -1.30 | 1.06 | 13.63 | 0.0667 | 1.32 | 1.43 | 179,863.40 | -8.45 | -- | -8.93 | -- | 53.54 | -- | -126.60 | -- | 13.60 | -- | 0.0214 | -- | -67.15 | -- | -153.00 | -- | -- | -- |
| Nanjing Medlander Medical Tech Co Ltd | 380.95m | 101.15m | 2.60bn | 481.00 | 25.35 | 1.98 | -- | 6.81 | 1.02 | 1.02 | 3.86 | 13.10 | 0.2527 | 1.98 | 21.47 | 791,989.40 | 7.06 | -- | 7.76 | -- | 71.46 | -- | 27.94 | -- | 7.57 | -- | 0.0115 | -- | -9.57 | -- | -26.19 | -- | -- | -- |
| Beijing Hotgen Biotech Co Ltd | 520.50m | -67.64m | 2.80bn | 1.04k | -- | 0.8585 | -- | 5.38 | -0.7349 | -0.7349 | 5.74 | 35.25 | 0.1484 | 2.20 | 5.85 | 502,410.60 | -2.13 | 29.65 | -2.22 | 34.70 | 46.98 | 56.08 | -14.33 | 32.26 | 8.95 | -- | 0.0026 | 41.92 | -84.78 | 23.67 | -97.10 | -10.67 | 57.98 | -- |
| Chemclin Diagnostics Co Ltd | 443.86m | 139.29m | 2.93bn | 731.00 | 21.00 | 2.09 | -- | 6.60 | 0.3476 | 0.3476 | 1.11 | 3.49 | 0.2491 | 1.00 | 16.34 | 607,195.30 | 7.82 | 11.01 | 8.73 | 12.32 | 74.89 | 74.19 | 31.38 | 31.07 | 5.16 | -- | 0.1515 | 36.64 | -4.28 | 4.00 | -3.44 | -- | 44.10 | -- |
| Nanjing Vishee Medical Technology Co Ltd | 422.21m | 112.74m | 2.96bn | 700.00 | 26.16 | 1.84 | -- | 7.01 | 1.18 | 1.18 | 4.42 | 16.83 | 0.2401 | 3.12 | 12.37 | 603,153.40 | 6.41 | 10.27 | 6.92 | 11.43 | 70.21 | 73.26 | 26.70 | 33.99 | 8.31 | -- | 0.0003 | 47.57 | 43.72 | 17.34 | 45.22 | 16.55 | 26.69 | -- |
| Beijing Succeeder Technology Inc | 297.74m | 112.75m | 3.03bn | 296.00 | 26.95 | 1.85 | -- | 10.18 | 1.06 | 1.06 | 2.80 | 15.41 | 0.1766 | 2.51 | 8.66 | 1,005,870.00 | 6.69 | 7.77 | 7.02 | 8.25 | 60.39 | 61.03 | 37.85 | 38.34 | 14.78 | -- | 0.00004 | 22.22 | 20.40 | 6.60 | 12.29 | 15.57 | 99.03 | -- |
| Cowealth Medical China Co Ltd | 970.41m | 29.67m | 3.04bn | 240.00 | 102.39 | 2.60 | -- | 3.13 | 0.0745 | 0.0745 | 2.44 | 2.93 | 0.6435 | 3.90 | 1.25 | 4,043,355.00 | 2.01 | 5.80 | 2.59 | 8.09 | 19.62 | 20.74 | 3.13 | 6.14 | 3.65 | -- | 0.0829 | 23.89 | -14.62 | 3.85 | -42.96 | -6.75 | 32.85 | -- |
| Hangzhou Biotest Biotech Co Ltd | 518.65m | 104.29m | 3.21bn | 629.00 | 30.40 | 1.35 | -- | 6.19 | 0.9897 | 0.9897 | 4.94 | 22.27 | 0.204 | 2.61 | 6.85 | 824,563.60 | 4.01 | 29.45 | 4.23 | 33.30 | 52.42 | 56.83 | 19.64 | 41.59 | 12.53 | -- | 0.0003 | 29.32 | -76.75 | 19.65 | -86.22 | 41.33 | 34.82 | -- |
Data as of Nov 15 2024. Currency figures normalised to Beijing Hotgen Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
2.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024 | 1.13m | 1.23% |
| Guolian Fund Management Co. Ltd.as of 30 Jun 2024 | 643.42k | 0.70% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 467.65k | 0.51% |
| Maxwealth Fund Management Co., Ltd.as of 30 Jun 2024 | 173.10k | 0.19% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 59.54k | 0.07% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2024 | 18.38k | 0.02% |
| Great Wall Fund Management Co., Ltd.as of 30 Jun 2024 | 16.76k | 0.02% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 14.35k | 0.02% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 12.51k | 0.01% |
| CCB Principal Asset Management Co., Ltd.as of 30 Jun 2024 | 11.10k | 0.01% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
